Last update
5/15/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 8 Researches
6.1
USERS' SCORE
Good
Based on 1 Review
8.4
Supplement Facts
Serving Size: 1 Veggie Capsule
Amount Per Serving
%DV
Coenzyme Q10 (Ubiquinone)
100 mg
†
Black Pepper Ext. (Piper nigrum) (fruit) (standardized to contain 95% Piperine) (BioPerine®)
5 mg
†
Top Medical Research Studies
9
We explored the effects of coenzyme Q (CoQ) on triple-negative breast cancer (TNBC) cells, specifically its ability to counteract inflammation, metastasis, and atypical metabolism associated with the disease. The study looked closely at how CoQ interferes with the activity of HIF-1α, a protein that plays a significant role in cancer progression.
Our findings showed that CoQ effectively inhibited the NLRP3 inflammasome, which is involved in inflammatory responses, as well as reduced harmful markers associated with cancer stem cells. We also observed that CoQ promotes a switch from a more aggressive, invasive cellular behavior to a less aggressive form by enhancing the expression of E-cadherin, an important marker for cell adhesion, while lowering N-cadherin, which is linked to aggression in cancer cells.
Furthermore, we noted that CoQ disrupts the Warburg effect—where cancer cells adapt their metabolism to thrive under low oxygen conditions. It inhibited key glycolytic pathways, leading to decreased glucose uptake and reduced lactate accumulation, while enhancing mitochondrial function. This shift toward better energy production could significantly impact the treatment of TNBC.
Overall, our research highlighted how CoQ's ability to suppress HIF-1α expressions contributes to its potential in managing a variety of aggressive traits in TNBC, making it a promising area for further investigation and possible therapeutic application.
Our findings showed that CoQ effectively inhibited the NLRP3 inflammasome, which is involved in inflammatory responses, as well as reduced harmful markers associated with cancer stem cells. We also observed that CoQ promotes a switch from a more aggressive, invasive cellular behavior to a less aggressive form by enhancing the expression of E-cadherin, an important marker for cell adhesion, while lowering N-cadherin, which is linked to aggression in cancer cells.
Furthermore, we noted that CoQ disrupts the Warburg effect—where cancer cells adapt their metabolism to thrive under low oxygen conditions. It inhibited key glycolytic pathways, leading to decreased glucose uptake and reduced lactate accumulation, while enhancing mitochondrial function. This shift toward better energy production could significantly impact the treatment of TNBC.
Overall, our research highlighted how CoQ's ability to suppress HIF-1α expressions contributes to its potential in managing a variety of aggressive traits in TNBC, making it a promising area for further investigation and possible therapeutic application.
Read More
8
MitoQ's potential in cancer treatment
We explored how coenzyme Q10, particularly in its mitochondria-targeted form known as MitoQ, impacts breast cancer cells. This study focused on its ability to inhibit cell growth and prevent metastasis in various cancer types, including aggressive triple-negative breast cancer.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
Read More
3
Coenzyme Q10 levels decrease in cancer
We aimed to understand the role of coenzyme Q10 in breast cancer by evaluating its levels in patients compared to healthy individuals. Our study involved 90 women, all divided into two groups: 60 who had been diagnosed with breast cancer and 30 healthy controls.
We discovered that the average levels of coenzyme Q10 were significantly lower in the women with breast cancer, standing at 16.91, while healthy participants had an average of 42.49. This difference was not just small; it was statistically significant, indicating that the levels of this coenzyme play a notable role in the health of breast cancer patients.
When we looked closer, we found varying levels of coenzyme Q10 among different stages of breast cancer. For instance, women at stage 1 had higher averages (28.03) compared to those in stage 2 (17.51), stage 3 (22.71), and metastatic stage (17.93). Regardless of the stage, all were still significantly lower than those in the healthy group.
Ultimately, our findings suggest a clear link: women with breast cancer have decreased levels of coenzyme Q10 compared to individuals without the disease. However, the study does not indicate that coenzyme Q10 directly benefits breast cancer treatment or proliferation.
We discovered that the average levels of coenzyme Q10 were significantly lower in the women with breast cancer, standing at 16.91, while healthy participants had an average of 42.49. This difference was not just small; it was statistically significant, indicating that the levels of this coenzyme play a notable role in the health of breast cancer patients.
When we looked closer, we found varying levels of coenzyme Q10 among different stages of breast cancer. For instance, women at stage 1 had higher averages (28.03) compared to those in stage 2 (17.51), stage 3 (22.71), and metastatic stage (17.93). Regardless of the stage, all were still significantly lower than those in the healthy group.
Ultimately, our findings suggest a clear link: women with breast cancer have decreased levels of coenzyme Q10 compared to individuals without the disease. However, the study does not indicate that coenzyme Q10 directly benefits breast cancer treatment or proliferation.
Read More
Most Useful Reviews
7.5
Raises morale
29 people found this helpful
I was advised to take this by Dr Mohamed Al-Fayed while dealing with my breast cancer diagnosis. It has significantly raised my morale during a difficult time of tumour removal. I believe it's a powerful antioxidant, and I've been encouraged after speaking with medical professionals about its benefits.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 8 Researches
6.1
- All Researches
9
We explored the effects of coenzyme Q (CoQ) on triple-negative breast cancer (TNBC) cells, specifically its ability to counteract inflammation, metastasis, and atypical metabolism associated with the disease. The study looked closely at how CoQ interferes with the activity of HIF-1α, a protein that plays a significant role in cancer progression.
Our findings showed that CoQ effectively inhibited the NLRP3 inflammasome, which is involved in inflammatory responses, as well as reduced harmful markers associated with cancer stem cells. We also observed that CoQ promotes a switch from a more aggressive, invasive cellular behavior to a less aggressive form by enhancing the expression of E-cadherin, an important marker for cell adhesion, while lowering N-cadherin, which is linked to aggression in cancer cells.
Furthermore, we noted that CoQ disrupts the Warburg effect—where cancer cells adapt their metabolism to thrive under low oxygen conditions. It inhibited key glycolytic pathways, leading to decreased glucose uptake and reduced lactate accumulation, while enhancing mitochondrial function. This shift toward better energy production could significantly impact the treatment of TNBC.
Overall, our research highlighted how CoQ's ability to suppress HIF-1α expressions contributes to its potential in managing a variety of aggressive traits in TNBC, making it a promising area for further investigation and possible therapeutic application.
Our findings showed that CoQ effectively inhibited the NLRP3 inflammasome, which is involved in inflammatory responses, as well as reduced harmful markers associated with cancer stem cells. We also observed that CoQ promotes a switch from a more aggressive, invasive cellular behavior to a less aggressive form by enhancing the expression of E-cadherin, an important marker for cell adhesion, while lowering N-cadherin, which is linked to aggression in cancer cells.
Furthermore, we noted that CoQ disrupts the Warburg effect—where cancer cells adapt their metabolism to thrive under low oxygen conditions. It inhibited key glycolytic pathways, leading to decreased glucose uptake and reduced lactate accumulation, while enhancing mitochondrial function. This shift toward better energy production could significantly impact the treatment of TNBC.
Overall, our research highlighted how CoQ's ability to suppress HIF-1α expressions contributes to its potential in managing a variety of aggressive traits in TNBC, making it a promising area for further investigation and possible therapeutic application.
Read More
8
MitoQ's potential in cancer treatment
We explored how coenzyme Q10, particularly in its mitochondria-targeted form known as MitoQ, impacts breast cancer cells. This study focused on its ability to inhibit cell growth and prevent metastasis in various cancer types, including aggressive triple-negative breast cancer.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
Read More
7
We explored the effects of coenzyme Q10 (CoQ) and its associated enzyme, UBIAD1, on breast cancer progression. Our study revealed that CoQ plays an important role in influencing the mechanical properties of cancer cells, particularly their stiffness. Interestingly, both CoQ and UBIAD1 were shown to increase the fluidity of the cell membrane, which resulted in stiffer cancer cells.
Additionally, we found that these factors could disrupt key signaling mechanisms within the extracellular matrix (ECM), leading to reduced resistance to ferroptosis, a type of cell death that is crucial in cancer treatment settings. Through analyses involving human patients and mouse models, we discovered that a loss of UBIAD1 is linked to breast cancer development and progression. This implies that maintaining UBIAD1 levels could potentially limit the survival of circulating tumor cells and prevent metastasis, particularly to the lungs.
Overall, our findings shed light on the potential of CoQ and UBIAD1 as targets for developing new therapeutic strategies to assist breast cancer patients, especially those facing a poor prognosis.
Additionally, we found that these factors could disrupt key signaling mechanisms within the extracellular matrix (ECM), leading to reduced resistance to ferroptosis, a type of cell death that is crucial in cancer treatment settings. Through analyses involving human patients and mouse models, we discovered that a loss of UBIAD1 is linked to breast cancer development and progression. This implies that maintaining UBIAD1 levels could potentially limit the survival of circulating tumor cells and prevent metastasis, particularly to the lungs.
Overall, our findings shed light on the potential of CoQ and UBIAD1 as targets for developing new therapeutic strategies to assist breast cancer patients, especially those facing a poor prognosis.
Read More
7
CoQ10 shows promise in breast cancer
We examined how coenzyme Q10 (CoQ10) supplementation affects breast cancer, focusing specifically on its role in reducing inflammation and oxidative stress. Our analysis was based on a systematic review of five randomized controlled trials, which included nine trials overall.
Through our research, we discovered that CoQ10 might effectively lower certain inflammatory markers and matrix metalloproteinase levels, which are key factors in breast cancer progression. Notably, while these results suggest benefits, it is essential to recognize that CoQ10 was primarily used alongside conventional chemotherapy, so pinpointing its standalone effects can be complex.
Overall, we see promise in CoQ10 as a supportive treatment in breast cancer care. However, we also acknowledge the need for more detailed studies covering various cancer types to deepen our understanding of its potential benefits in tumor therapy.
Through our research, we discovered that CoQ10 might effectively lower certain inflammatory markers and matrix metalloproteinase levels, which are key factors in breast cancer progression. Notably, while these results suggest benefits, it is essential to recognize that CoQ10 was primarily used alongside conventional chemotherapy, so pinpointing its standalone effects can be complex.
Overall, we see promise in CoQ10 as a supportive treatment in breast cancer care. However, we also acknowledge the need for more detailed studies covering various cancer types to deepen our understanding of its potential benefits in tumor therapy.
Read More
We conducted a clinical trial to investigate the impact of coenzyme Q10 (CoQ10) on certain inflammatory markers in women diagnosed with breast cancer who were also receiving tamoxifen therapy. Our study involved 30 breast cancer patients and 29 healthy participants, randomly divided into groups. Those in the intervention groups received 100 mg of CoQ10 daily for two months, while the control groups were given a placebo.
After the study period, we analyzed blood samples to measure levels of interleukin 6, interleukin 8, and vascular endothelial growth factor (VEGF). These markers are often associated with inflammation and cancer progression. Our findings suggest that CoQ10 supplementation may play a role in lowering levels of these inflammatory cytokines, which could help alleviate some of the inflammation related to breast cancer.
However, it’s essential to note that while there were positive indications, the results also suggest the need for larger and longer studies to confirm these effects. Future research should take into account both the potential benefits and any risks involved with higher doses of CoQ10.
After the study period, we analyzed blood samples to measure levels of interleukin 6, interleukin 8, and vascular endothelial growth factor (VEGF). These markers are often associated with inflammation and cancer progression. Our findings suggest that CoQ10 supplementation may play a role in lowering levels of these inflammatory cytokines, which could help alleviate some of the inflammation related to breast cancer.
However, it’s essential to note that while there were positive indications, the results also suggest the need for larger and longer studies to confirm these effects. Future research should take into account both the potential benefits and any risks involved with higher doses of CoQ10.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Raises morale
29 people found this helpful
I was advised to take this by Dr Mohamed Al-Fayed while dealing with my breast cancer diagnosis. It has significantly raised my morale during a difficult time of tumour removal. I believe it's a powerful antioxidant, and I've been encouraged after speaking with medical professionals about its benefits.
Read More
Frequently Asked Questions
7.5
Raises morale
29 people found this helpful
I was advised to take this by Dr Mohamed Al-Fayed while dealing with my breast cancer diagnosis. It has significantly raised my morale during a difficult time of tumour removal. I believe it's a powerful antioxidant, and I've been encouraged after speaking with medical professionals about its benefits.
3
Coenzyme Q10 levels decrease in cancer
We aimed to understand the role of coenzyme Q10 in breast cancer by evaluating its levels in patients compared to healthy individuals. Our study involved 90 women, all divided into two groups: 60 who had been diagnosed with breast cancer and 30 healthy controls.
We discovered that the average levels of coenzyme Q10 were significantly lower in the women with breast cancer, standing at 16.91, while healthy participants had an average of 42.49. This difference was not just small; it was statistically significant, indicating that the levels of this coenzyme play a notable role in the health of breast cancer patients.
When we looked closer, we found varying levels of coenzyme Q10 among different stages of breast cancer. For instance, women at stage 1 had higher averages (28.03) compared to those in stage 2 (17.51), stage 3 (22.71), and metastatic stage (17.93). Regardless of the stage, all were still significantly lower than those in the healthy group.
Ultimately, our findings suggest a clear link: women with breast cancer have decreased levels of coenzyme Q10 compared to individuals without the disease. However, the study does not indicate that coenzyme Q10 directly benefits breast cancer treatment or proliferation.
We discovered that the average levels of coenzyme Q10 were significantly lower in the women with breast cancer, standing at 16.91, while healthy participants had an average of 42.49. This difference was not just small; it was statistically significant, indicating that the levels of this coenzyme play a notable role in the health of breast cancer patients.
When we looked closer, we found varying levels of coenzyme Q10 among different stages of breast cancer. For instance, women at stage 1 had higher averages (28.03) compared to those in stage 2 (17.51), stage 3 (22.71), and metastatic stage (17.93). Regardless of the stage, all were still significantly lower than those in the healthy group.
Ultimately, our findings suggest a clear link: women with breast cancer have decreased levels of coenzyme Q10 compared to individuals without the disease. However, the study does not indicate that coenzyme Q10 directly benefits breast cancer treatment or proliferation.
7
CoQ10 shows promise in breast cancer
We examined how coenzyme Q10 (CoQ10) supplementation affects breast cancer, focusing specifically on its role in reducing inflammation and oxidative stress. Our analysis was based on a systematic review of five randomized controlled trials, which included nine trials overall.
Through our research, we discovered that CoQ10 might effectively lower certain inflammatory markers and matrix metalloproteinase levels, which are key factors in breast cancer progression. Notably, while these results suggest benefits, it is essential to recognize that CoQ10 was primarily used alongside conventional chemotherapy, so pinpointing its standalone effects can be complex.
Overall, we see promise in CoQ10 as a supportive treatment in breast cancer care. However, we also acknowledge the need for more detailed studies covering various cancer types to deepen our understanding of its potential benefits in tumor therapy.
Through our research, we discovered that CoQ10 might effectively lower certain inflammatory markers and matrix metalloproteinase levels, which are key factors in breast cancer progression. Notably, while these results suggest benefits, it is essential to recognize that CoQ10 was primarily used alongside conventional chemotherapy, so pinpointing its standalone effects can be complex.
Overall, we see promise in CoQ10 as a supportive treatment in breast cancer care. However, we also acknowledge the need for more detailed studies covering various cancer types to deepen our understanding of its potential benefits in tumor therapy.
4
We evaluated the impact of coenzyme Q10 (CoQ10) on breast cancer in the context of a study that assessed the effects of various drug combinations. Specifically, we focused on how CoQ10 interacts with other treatments, such as Simvastatin, paclitaxel, and GM-CSF. Through a series of tests, including cytotoxicity assessment and flow cytometry, we investigated this combination therapy's potential to influence cancer cell behavior.
Our findings indicated that while CoQ10 alone is not highlighted for its direct anti-cancer effects on breast cancer specifically, when paired with treatments like 2-Aminoethyl Dihydrogen Phosphate (2-AEH2P), there were some notable synergistic benefits. This means that the combined use of these agents showed enhanced effectiveness compared to when used individually.
However, it is important to note that the study did not provide evidence of CoQ10 having a significant isolated benefit for breast cancer treatment. Instead, its role appears more supportive when combined with other drugs, pointing towards a more complex interaction rather than a straightforward effectiveness on its own.
Overall, we observed the significance of exploring coenzyme Q10 as part of a broader treatment regimen, rather than in isolation, when considering its potential in treating breast cancer.
Our findings indicated that while CoQ10 alone is not highlighted for its direct anti-cancer effects on breast cancer specifically, when paired with treatments like 2-Aminoethyl Dihydrogen Phosphate (2-AEH2P), there were some notable synergistic benefits. This means that the combined use of these agents showed enhanced effectiveness compared to when used individually.
However, it is important to note that the study did not provide evidence of CoQ10 having a significant isolated benefit for breast cancer treatment. Instead, its role appears more supportive when combined with other drugs, pointing towards a more complex interaction rather than a straightforward effectiveness on its own.
Overall, we observed the significance of exploring coenzyme Q10 as part of a broader treatment regimen, rather than in isolation, when considering its potential in treating breast cancer.
8
MitoQ's potential in cancer treatment
We explored how coenzyme Q10, particularly in its mitochondria-targeted form known as MitoQ, impacts breast cancer cells. This study focused on its ability to inhibit cell growth and prevent metastasis in various cancer types, including aggressive triple-negative breast cancer.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
Our investigations revealed that MitoQ significantly reduced tumor growth and proliferation in laboratory settings, suggesting it could be a valuable tool in breast cancer treatment. Interestingly, the study also examined a modified version of MitoQ, called dimethoxy MitoQ (DM-MitoQ), which does not possess antioxidant properties but surprisingly showed even greater potency in inhibiting cell growth.
Both compounds hindered mitochondrial oxygen consumption, key to cancer cell survival. This leads us to conclude that the ability to disrupt mitochondrial function might be what makes MitoQ and its analog effective against breast cancer cell proliferation.
Importantly, using DM-MitoQ as a negative control supports the idea that the oxidative damage pathway could be crucial in cancer treatments, adding an exciting dimension to how we approach oxidative stress in cancer therapies.
References
- Tosi G, Paoli A, Zuccolotto G, Turco E, Simonato M, et al. Cancer cell stiffening via CoQ and UBIAD1 regulates ECM signaling and ferroptosis in breast cancer. Nat Commun. 2024;15:8214. 10.1038/s41467-024-52523-y
- Alves MG, Cabral LGS, Totti PGF, Azarias FR, Pomini KT, et al. 2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor. Biomedicines. 2024;12. 10.3390/biomedicines12010109
- Abd-Alqader F, Sarhat E, Zaidan Z. EVALUATION OF THE ROLE OF COENZYME Q 10 IN THE BLOOD OF BREAST CANCER WOMEN. Georgian Med News. 2023. PubMed
- Cheng G, Karoui H, Hardy M, Kalyanaraman B. Redox-crippled MitoQ potently inhibits breast cancer and glioma cell proliferation: A negative control for verifying the antioxidant mechanism of MitoQ in cancer and other oxidative pathologies. Free Radic Biol Med. 2023;205:175. 10.1016/j.freeradbiomed.2023.06.009
- Yang HL, Lin PY, Vadivalagan C, Lin YA, Lin KY, et al. Coenzyme Q defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells. Arch Toxicol. 2023;97:1047. 10.1007/s00204-023-03456-w
- Alimohammadi M, Rahimi A, Faramarzi F, Golpour M, Jafari-Shakib R, et al. Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: a systematic review and meta-analysis of randomized controlled- trials. Inflammopharmacology. 2021;29:579. 10.1007/s10787-021-00817-8
- Abdi S, Montazeri V, Garjani A, Shayanfar A, Pirouzpanah S. Coenzyme Q10 in association with metabolism-related AMPK/PFKFB3 and angiogenic VEGF/VEGFR2 genes in breast cancer patients. Mol Biol Rep. 2020;47:2459. 10.1007/s11033-020-05310-z
- Zahrooni N, Hosseini SA, Ahmadzadeh A, Ahmadi Angali K, Assarehzadegan MA. The Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Growth Factor and Serum Levels of Interleukin 6 and 8 in Women with Breast Cancer: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Ther Clin Risk Manag. 2019;15:1403. 10.2147/TCRM.S234930
